Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network-Reference-Cited by-同舟云学术

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

Published:2023-06 Issue:6 Volume:24 Page:e255-e269
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ludwig Heinz,Terpos Evangelos,van de Donk Niels,Mateos Maria-Victoria,Moreau Philippe,Dimopoulos Melitios-Athanasios,Delforge Michel,Rodriguez-Otero Paula,San-Miguel Jesús,Yong Kwee,Gay Francesca,Einsele Hermann,Mina Roberto,Caers Jo,Driessen Christoph,Musto Pellegrino,Zweegman Sonja,Engelhardt Monika,Cook Gordon,Weisel Katja,Broijl Annemiek,Beksac Meral,Bila Jelena,Schjesvold Fredrik,Cavo Michele,Hajek Roman,Touzeau Cyrille,Boccadoro Mario,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Oncology

Reference68 articles.

1. Management of immune-related adverse events in patients treated with chimeric antigen receptor t-cell therapy: ASCO guideline;Santomasso;J Clin Oncol,2021

2. Teclistamab in relapsed or refractory multiple myeloma;Moreau;N Engl J Med,2022

3. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma;Chari;N Engl J Med,2022

4. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma;Raje;Blood,2022

5. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the MagnetisMM-3 study;Bahlis;Blood,2022

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards personalized and rational use of immunoglobulins amid expanding indications and shortages;Transfusion and Apheresis Science;2024-10

2. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy;Pharmacological Research;2024-10

3. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

4. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma;Annals of Pharmacotherapy;2024-08-27